The world is looking forward to a coronavirus vaccine to control the ongoing pandemic. Meanwhile, the Novavax coronavirus vaccine showed positive results in its experimental trial. The trial included 100 individuals from Australia. The vaccine triggered an immune response in all of the participants during the first trial.
The report was published recently in the New England Journal of Medicine (NEJM).
The Novavax coronavirus vaccine had no significant side effects in the first phase. Novavax also announced that 2nd half of this trial launched. This phase includes participants from Australia and the US. These individuals are aged 60 to 84 years old.
The Novavax shares increased by four percent after they published the results from the trial.
The Novavax coronavirus vaccine is called NVX-CoV2373. The first phase of this trial included 108 participants. These individuals were aged from 18 to 59 years old. 83 participants received the vaccine containing a booster for immune response. All of the individuals received two shots of the vaccine.
The individuals who received the vaccine containing the additional booster had antibodies developed against coronavirus. The antibodies target the specific protein present on the coronavirus surface.
Some participants also showed neutralizing antibodies in response to the vaccine. These antibodies are highly capable of preventing the virus from entering the cells of the body.
All of the participants developed antibodies against the virus after two doses. The antibodies developed in the body after the vaccine were higher than those of a person who recovered from coronavirus infection.
The second phase will include 1500 adult participants from Australia and the US. Novavax will present the results from this trial before the end of this year. The first trial of the Novavax coronavirus vaccine showed promising results in the first phase of clinical trials.
Novavax has developed a vaccine for the first time. The vaccine produced by the company consists of proteins present on the surface of coronavirus. This protein helps the virus enter the cells of the human body.
The synthetic surface protein stimulates the immune system to produce antibodies against the coronavirus. The next phase of the trial will further test the ability of this vaccine. The researchers will also test if the vaccine helps prevent coronavirus infection in a larger number of participants.
An effective coronavirus vaccine is the need of the hour. It is the only hope to stop the pandemic from taking more lives. The virus has already infected millions of individuals across the globe. The virus will continue to spread unless there is a vaccine or treatment available.
Several countries are developing vaccines against the infection caused by the novel coronavirus. However, the authorities will keep a close check to see the safety of the shots being developed.
The efficacy of a vaccine is important for it to be effective against the virus. However, it is also important that the vaccine does not have any side effects. The Novavax coronavirus vaccine does not have any significant side effects so far. The researchers will test the vaccine further in more participants to test its efficacy and safety.